Latest news with #InfluxHealthtech
Business Standard
4 days ago
- Business
- Business Standard
NSE SME Influx Healthtech makes a strong debut
Shares of Influx Healthtech were trading at Rs 130 on the NSE, a premium of 35.42% compared with the issue price of Rs 96. The scrip was listed at Rs 132.50, a premium of 38.02% compared with the initial public offer (IPO) price. The stock was currently down 1.9% over its listing price. The counter hit a high of Rs 135.85 and a low of Rs 125.90. About 28.55 lakh shares of the company changed hands at the counter. Influx Healthtech's IPO was subscribed 187.31 times. The issue opened for bidding on 18 June 2025 and it closed on 20 June 2025. The price band of the IPO was fixed at Rs 91 to Rs 96 per share. The IPO of 61,00,800 equity shares comprised a fresh issue of 50,00,400 equity shares and offer for sale (OFS) of 11,00,400 equity shares. The promoter and promoter group shareholding diluted to 73.53% from 99.85% pre-issue. The company intends to utilize the net proceeds for funding capital expenditure requirements for setting up of manufacturing facility for nutraceutical division, funding capital expenditure requirements for setting up of manufacturing facility for veterinary food division, purchase of machineries for homecare and cosmetic division and general corporate expenses. Ahead of the Influx Healthtech on 17 June 2025, raised Rs 16.66 crore from anchor investors. The board has allotted 17.36 lakh shares at Rs 96 per share to 8 anchor investors. Influx Healthtech is a Mumbai-based, healthcare focused company specialising in contract manufacturing. Since its inception in 2020, the company has established itself as a reliable contract development and manufacturing organization (CDMO). The company offers comprehensive production services across a wide range of categories, including dietary and nutritional supplements, cosmetics, ayurvedic and herbal products, veterinary feed supplements, homecare products, active pharmaceutical ingredients (APIs), and finished dosage forms such as tablets, capsules and injectables. The company had a total workforce of 163 permanent employees on a payroll basis. The company recorded revenue from operations of Rs 104.85 crore and net profit of Rs 13.37 crore for the period ended 31 March 2025.
Economic Times
4 days ago
- Business
- Economic Times
Influx Healthtech shares list at 38% premium over IPO price on NSE SME
Influx Healthtech debuted strongly on the NSE SME platform, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs 96. The Rs 58.57 crore IPO, which closed on June 20, surpassed grey market expectations. Tired of too many ads? Remove Ads IPO Overview Tired of too many ads? Remove Ads Popular in Markets 1. HAL shares in focus as delay-hit Tejas jets to reach IAF by March Company background Financials and Valuation Healthcare-focused contract manufacturer Influx Healthtech made a strong debut on the NSE SME platform today, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs Rs 58.57 crore IPO had closed for subscription on June of the listing, the grey market premium (GMP) for Influx Healthtech stood at around Rs 20, implying an expected listing price of Rs 116 — a potential gain of 20.83%. However, the stock surpassed grey market expectations with a significantly stronger IPO comprised a fresh issue of 50 lakh shares worth Rs 48 crore and an offer for sale (OFS) of 11 lakh shares worth Rs 10.56 crore, offering a total of 61,00,800 shares. The IPO price was fixed at Rs 96 per anchor portion attracted Rs 16.67 crore, with shares allocated to institutional investors a day before the issue in 2020, Influx Healthtech is a CDMO (Contract Development and Manufacturing Organization) providing end-to-end manufacturing and product development services for nutraceuticals, cosmetics, personal care, ayurvedic, veterinary, and homecare out of three modern facilities in Thane, Maharashtra, the company boasts an extensive portfolio including gummies, capsules, powders, skincare products, herbal supplements, and veterinary feed formulations. It serves nutraceutical, cosmetic, and healthcare clients, handling everything from formulation and R&D to regulatory support and company currently employs 163 people and continues to expand its product capabilities and client reach, focusing on innovation and scalability in fast-growing consumer health Healthtech posted a revenue of Rs 104.99 crore in FY25, up 5% year-on-year, while PAT rose 19% to Rs 13.37 crore. It maintains a robust ROE of 36.98%, EBITDA margin of 19.62%, and negligible debt.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Influx Healthtech lists at 38% premium on NSE SME, beats GMP estimates
Influx Healthtech IPO listing today: Shares of healthcare-focused contract manufacturer Influx Healthtech made a robust market debut on Wednesday, June 25, 2025, listing at ₹132.5 on the NSE SME platform, a premium of 38 per cent from its issue price of ₹96 per share. After the listing, shares of Influx Healthtech were trading at 127.5, down 3.77 per cent from the opening price. Influx Healthtech debut was significantly above the grey market expectations. Ahead of listing, the unlisted shares of Influx Healthtech were trading ₹116, reflecting a premium of ₹20 or 20.8 per cent against the issue price. Influx Healthtech IPO subscription The company offered shares in the price band of ₹91 to ₹96 with a lot size of 1,200 shares. It received bids for 81,75,38,400 shares against the 40,58,400 shares offered, resulting in an oversubscription of 201 times by the end of the subscription period, showed NSE data. Influx Healthtech IPO details Influx Healthtech IPO was combination of fresh issue of 5 million equity shares to raise ₹48 crore and offer for sale (OFS) of 1.1 million equity shares aggregating to ₹10.56 crore. Influx Healthtech IPO was available for subscription from Wednesday, June 18, 2025, till Friday, June 20, 2025. The basis of allotment of shares was finalised on Monday, June 23, 2025. Maashitla Securities was the registrar of the issue. Rarever Financial Advisors was the book-running lead manager of the Influx Healthtech IPO. According to the red herring prospectus (RHP), the company plans to use the net fresh issue proceeds to set up a manufacturing facility for Nutraceutical Division, another manufacturing facility for Veterinary Food Division, and purchase of machinery for homecase and cosmetic division. The remaining funds will be used for general corporate purposes. About Influx Healthtech Incorporated in 2020, Influx Healthtech is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates three manufacturing units in Thane, Maharashtra. The company's expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (API), and finished dosage forms, including tablets, capsules and injectables.
Economic Times
4 days ago
- Business
- Economic Times
Influx Healthtech IPO debut today: GMP signals moderate listing buzz
As per the latest update, the grey market premium (GMP) stands at Rs 20, translating to an expected listing price of Rs 116 per share, over the IPO price of Rs 96 — a potential 20.83% gain on listing. Synopsis Influx Healthtech is set to debut on the NSE SME platform today after its Rs 58.57 crore IPO. The IPO price was fixed at Rs 96 per share. The company, a CDMO established in 2020, offers manufacturing and product development services for nutraceuticals, cosmetics, and other healthcare products, operating from facilities in Thane, Maharashtra. Healthcare-focused contract manufacturer Influx Healthtech is set to make its market debut on the NSE SME platform today. The Rs 58.57 crore IPO, which concluded its bidding on June 20, has entered the final leg of its public issue journey, with allotments wrapped up and shares ready for listing. ADVERTISEMENT As per the latest update, the grey market premium (GMP) stands at Rs 20, translating to an expected listing price of Rs 116 per share, over the IPO price of Rs 96 — a potential 20.83% gain on listing. The IPO comprised a fresh issue of 50 lakh shares worth Rs 48 crore and an offer for sale (OFS) of 11 lakh shares worth Rs 10.56 crore, offering a total of 61,00,800 shares. The IPO price was fixed at Rs 96 per share. The anchor portion attracted Rs 16.67 crore, with shares allocated to institutional investors a day before the issue in 2020, Influx Healthtech is a CDMO (Contract Development and Manufacturing Organization) providing end-to-end manufacturing and product development services for nutraceuticals, cosmetics, personal care, ayurvedic, veterinary, and homecare products. ADVERTISEMENT Operating out of three modern facilities in Thane, Maharashtra, the company boasts an extensive portfolio including gummies, capsules, powders, skincare products, herbal supplements, and veterinary feed formulations. It serves nutraceutical, cosmetic, and healthcare clients, handling everything from formulation and R&D to regulatory support and company currently employs 163 people and continues to expand its product capabilities and client reach, focusing on innovation and scalability in fast-growing consumer health segments. ADVERTISEMENT Influx Healthtech posted a revenue of Rs 104.99 crore in FY25, up 5% year-on-year, while PAT rose 19% to Rs 13.37 crore. It maintains a robust ROE of 36.98%, EBITDA margin of 19.62%, and negligible debt. ADVERTISEMENT (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel) Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Cyient shares fall over 9% after Q4 profit declines, core business underperforms Cyient shares fall over 9% after Q4 profit declines, core business underperforms L&T Technology Services shares slide 7% after Q4 profit dips L&T Technology Services shares slide 7% after Q4 profit dips Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? SEBI warns of securities market frauds via YouTube, Facebook, X and more SEBI warns of securities market frauds via YouTube, Facebook, X and more API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders Security, transparency, and innovation: What sets Pi42 apart in crypto trading Security, transparency, and innovation: What sets Pi42 apart in crypto trading Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains NEXT STORY
Time of India
4 days ago
- Business
- Time of India
Influx Healthtech IPO debut today: GMP signals moderate listing buzz
Healthcare-focused contract manufacturer Influx Healthtech is set to make its market debut on the NSE SME platform today. The Rs 58.57 crore IPO, which concluded its bidding on June 20, has entered the final leg of its public issue journey, with allotments wrapped up and shares ready for listing. As per the latest update, the grey market premium (GMP) stands at Rs 20, translating to an expected listing price of Rs 116 per share, over the IPO price of Rs 96 — a potential 20.83% gain on listing. IPO Overview The IPO comprised a fresh issue of 50 lakh shares worth Rs 48 crore and an offer for sale (OFS) of 11 lakh shares worth Rs 10.56 crore, offering a total of 61,00,800 shares. The IPO price was fixed at Rs 96 per share. The anchor portion attracted Rs 16.67 crore, with shares allocated to institutional investors a day before the issue opened. Company background Established in 2020, Influx Healthtech is a CDMO (Contract Development and Manufacturing Organization) providing end-to-end manufacturing and product development services for nutraceuticals, cosmetics, personal care, ayurvedic, veterinary, and homecare products. Operating out of three modern facilities in Thane, Maharashtra, the company boasts an extensive portfolio including gummies, capsules, powders, skincare products, herbal supplements, and veterinary feed formulations. It serves nutraceutical, cosmetic, and healthcare clients, handling everything from formulation and R&D to regulatory support and packaging. The company currently employs 163 people and continues to expand its product capabilities and client reach, focusing on innovation and scalability in fast-growing consumer health segments. Financials and Valuation Influx Healthtech posted a revenue of Rs 104.99 crore in FY25, up 5% year-on-year, while PAT rose 19% to Rs 13.37 crore. It maintains a robust ROE of 36.98%, EBITDA margin of 19.62%, and negligible debt. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
